CN113908343B - Biomaterial with improved bending performance - Google Patents
Biomaterial with improved bending performance Download PDFInfo
- Publication number
- CN113908343B CN113908343B CN202111160236.8A CN202111160236A CN113908343B CN 113908343 B CN113908343 B CN 113908343B CN 202111160236 A CN202111160236 A CN 202111160236A CN 113908343 B CN113908343 B CN 113908343B
- Authority
- CN
- China
- Prior art keywords
- biomaterial
- ubm
- improved bending
- properties according
- acellular matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 47
- 238000005452 bending Methods 0.000 title claims abstract description 32
- 239000011159 matrix material Substances 0.000 claims abstract description 14
- 210000004876 tela submucosa Anatomy 0.000 claims abstract description 8
- 210000002469 basement membrane Anatomy 0.000 claims abstract description 6
- 230000000968 intestinal effect Effects 0.000 claims abstract description 5
- 210000001691 amnion Anatomy 0.000 claims abstract description 4
- 210000004207 dermis Anatomy 0.000 claims abstract description 4
- 210000003516 pericardium Anatomy 0.000 claims abstract description 4
- 210000004303 peritoneum Anatomy 0.000 claims abstract description 4
- 238000003475 lamination Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000003387 muscular Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims 1
- 230000036571 hydration Effects 0.000 abstract description 15
- 238000006703 hydration reaction Methods 0.000 abstract description 15
- 239000002344 surface layer Substances 0.000 abstract description 15
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 230000002950 deficient Effects 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 20
- 239000000463 material Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000011229 interlayer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000012209 synthetic fiber Substances 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- PTHLSIBOMNYSIS-UHFFFAOYSA-N 5-(4-aminophenyl)-8-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=C(N)C=C1 PTHLSIBOMNYSIS-UHFFFAOYSA-N 0.000 description 2
- 208000021970 Abdominal wall defect Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010060954 Abdominal Hernia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 208000036838 Postoperative fever Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明针对生物材料水化后过于柔软,难以完全伸展,不易贴合缺损组织、不易缝合固定的技术问题,公开了一种弯曲性能改良的生物材料,包括脱细胞膀胱基底膜UBM和脱细胞基质,所述UBM完全包覆所述脱细胞基质,所述UBM的厚度为0.05‑0.2mm,所述脱细胞基质包括为小肠粘膜下层SIS、真皮、心包、羊膜、腹膜。在不增加生物材料总体厚度的前提下,引入不同厚度的脱细胞膀胱基底膜UBM表层,以改善、调节生物材料水化后的机械强度和柔软性。Aiming at the technical problems that the biological material is too soft after hydration, it is difficult to fully stretch, it is difficult to fit the defective tissue, and it is difficult to be sutured and fixed, the invention discloses a biological material with improved bending performance, including acellular bladder basement membrane UBM and acellular matrix , the UBM completely covers the acellular matrix, the thickness of the UBM is 0.05-0.2mm, and the acellular matrix includes small intestinal submucosa SIS, dermis, pericardium, amnion, and peritoneum. On the premise of not increasing the overall thickness of the biomaterial, different thicknesses of the UBM surface layer of the decellularized bladder basement membrane were introduced to improve and adjust the mechanical strength and softness of the biomaterial after hydration.
Description
技术领域technical field
本发明属于组织修复材料领域,尤其涉及一种弯曲性能改良的生物材料。The invention belongs to the field of tissue repair materials, in particular to a biological material with improved bending performance.
背景技术Background technique
脱细胞基质生物材料是软组织修补材料的发展趋势,其应用特点可以诱导“内源性组织再生”:植入后其内所含的生物信号或降解产物可以诱导修复区周围巨噬细胞和干细胞主动、快速浸润,生长、增殖并分泌自身细胞外基质替代植入物。随着宿主组织的长入,ACTM逐步降解,两者基本同步,最终ACTM完全被宿主组织代替。脱细胞基质生物材料目前已临床应用于替代脑膜、胸膜、腹壁筋膜等,吻合口加强、盆底重建、膀胱悬吊、肝脾等实质脏器破损填塞止血以及各种复杂疝和腹壁缺损的治疗如伴有污染的腹壁缺损、合成补片植入后感染、肠瘘二次手术治疗等。Acellular matrix biomaterials are the development trend of soft tissue repair materials, and their application characteristics can induce "endogenous tissue regeneration": after implantation, the biological signals or degradation products contained in them can induce macrophages and stem cells around the repair area to actively , Rapid infiltration, growth, proliferation and secretion of its own extracellular matrix to replace the implant. With the growth of host tissue, ACTM gradually degrades, and the two are basically synchronized, and finally ACTM is completely replaced by host tissue. Acellular matrix biomaterials have been clinically used to replace meninges, pleura, abdominal wall fascia, etc., to strengthen the anastomotic stoma, to reconstruct the pelvic floor, to suspend the bladder, to stop bleeding from solid organ damage such as liver and spleen, and to hemostasis of various complex hernias and abdominal wall defects. Treatment such as abdominal wall defect with contamination, infection after implantation of synthetic mesh, secondary surgery for intestinal fistula, etc.
对于植入人体时需要缝合固定的补片产品而言,过于柔软的材料应用时难以伸展,缝合难度较大;而过于硬挺的材料,无法贴合创面进行缝合;因此对补片的硬挺度这一指标进行调节具有显著的临床意义。在生物材料的临床应用过程中,不可避免的会与人体组织中的血液或组织也接触发生水化,因此评价生物材料水化后的硬挺度评价更符合临床试剂需求。而目前生物材料仅在干态时柔韧性良好,水化后立即柔软、不易贴合、不易缝合固定,增加医生的操作难度,延长手术操作时间。中国发明专利CN107335097A尝试在材料层间加入合成纤维以提升材料水化后的机械强度和柔韧性,但可降解合成纤维的降解产物为酸性物质,不利于缺损组织愈合;不可降解的合成纤维则可能导致材料皱缩、慢性侵蚀、疼痛等问题的发生。For patch products that need to be sutured and fixed when implanted into the human body, materials that are too soft are difficult to stretch when applied, and suture is more difficult; while materials that are too stiff cannot fit the wound for suturing; therefore, the stiffness of the patch is limited. Adjustment of one index has significant clinical significance. During the clinical application of biomaterials, it is inevitable that they will come into contact with blood or tissues in human tissues to cause hydration. Therefore, the evaluation of the stiffness of biomaterials after hydration is more in line with the needs of clinical reagents. At present, biomaterials are only good in flexibility when they are dry, and they are soft immediately after hydration, and are not easy to fit or suture and fix. This increases the difficulty of the doctor's operation and prolongs the operation time. Chinese invention patent CN107335097A attempts to add synthetic fibers between the material layers to improve the mechanical strength and flexibility of the material after hydration, but the degradation products of degradable synthetic fibers are acidic substances, which are not conducive to the healing of defective tissues; non-degradable synthetic fibers may Lead to material shrinkage, chronic erosion, pain and other problems.
发明内容Contents of the invention
本发明针对生物材料水化后过于柔软,难以完全伸展,不易贴合缺损组织、不易缝合固定的技术问题,提供一种弯曲性能改良的生物材料,在不增加生物材料总体厚度的前提下,引入不同厚度的脱细胞膀胱基底膜UBM表层,以改善、调节生物材料水化后的机械强度和柔软性。Aiming at the technical problems that the biological material is too soft after hydration, it is difficult to fully stretch, it is difficult to fit the defective tissue, and it is difficult to be sutured and fixed, the present invention provides a biological material with improved bending performance. UBM surface layer of decellularized bladder basement membrane with different thicknesses to improve and adjust the mechanical strength and softness of the biomaterial after hydration.
为实现上述目的,本发明的技术方案为:To achieve the above object, the technical solution of the present invention is:
一种弯曲性能改良的生物材料,包括脱细胞膀胱基底膜UBM和脱细胞基质,所述UBM完全包覆所述脱细胞基质,所述UBM的厚度为0.05-0.2mm,所述脱细胞基质为小肠黏膜下层SIS、心包、真皮、羊膜、腹膜等。A biomaterial with improved bending properties, comprising decellularized bladder basement membrane UBM and an acellular matrix, the UBM completely covers the acellular matrix, the thickness of the UBM is 0.05-0.2mm, and the acellular matrix is Small intestinal submucosa SIS, pericardium, dermis, amniotic membrane, peritoneum, etc.
所述生物材料完全水化10min后的弯曲长度降低不超过50%。The bending length of the biological material is not reduced by more than 50% after 10 minutes of complete hydration.
所述UBM由哺乳动物膀胱经机械方法除去浆膜、肌层、粘膜下层、粘膜肌层后脱细胞处理制得。The UBM is prepared from the mammalian bladder by mechanically removing the serosa, the muscular layer, the submucosa and the muscularis mucosae and then decellularized.
所述SIS由哺乳动物小肠经机械方法除去粘膜、浆膜层和肌层后脱细胞处理制得。The SIS is prepared from the mammalian small intestine by mechanically removing the mucous membrane, the serosa layer and the muscular layer and then decellularized.
所述生物材料还包括药物。The biological material also includes drugs.
所述药物借助介质分布于所述生物材料层间或表面,或层间和表面。层间为部分层间或各层间。The drug is distributed between layers or on the surface, or between layers and on the surface, of the biological material by means of a medium. The interlayer is part of the interlayer or each interlayer.
所述生物材料以所述SIS为中间层,所述UBM为上下表层,所述上下表层完全包覆中间层形成三明治结构。The biological material takes the SIS as the middle layer, and the UBM as the upper and lower surface layers, and the upper and lower surface layers completely cover the middle layer to form a sandwich structure.
UBM可为单层或多层结构。UBM can be a single-layer or multi-layer structure.
所述生物材料各层间以真空层压的方式固定。Each layer of the biological material is fixed by vacuum lamination.
所述真空层压的工艺参数为:真空压力为-50~-760mmHg,作用时间为0.5~72h。The process parameters of the vacuum lamination are: the vacuum pressure is -50--760mmHg, and the action time is 0.5-72h.
本发明由于采用以上技术方案,使其与现有技术相比具有以下的优点和积极效果:Compared with the prior art, the present invention has the following advantages and positive effects due to the adoption of the above technical scheme:
本发明将厚度范围为0.05-0.2mm的UBM作为生物材料的表层,该生物材料水化后依然能长时间保持材料的硬挺度,操作手感好,贴合度好,利于手术缝合操作,缩短补片固定时间。通过改变UBM表层的厚度,可以在不增加生物材料整体厚度的前提下进一步调整生物材料水化后的硬挺度。In the present invention, UBM with a thickness range of 0.05-0.2mm is used as the surface layer of the biological material. After the biological material is hydrated, it can still maintain the stiffness of the material for a long time. slice fixed time. By changing the thickness of the UBM surface layer, the stiffness of the biomaterial after hydration can be further adjusted without increasing the overall thickness of the biomaterial.
具体实施方式Detailed ways
以下结合具体实施例对本发明提出的一种弯曲性能改良的生物材料作进一步详细说明。根据下面说明,本发明的优点和特征将更清楚。A biomaterial with improved bending performance proposed by the present invention will be further described in detail below in conjunction with specific examples. The advantages and features of the present invention will become clearer from the following description.
一种弯曲性能改良的生物材料,包括脱细胞膀胱基底膜UBM和脱细胞基质,UBM完全包覆脱细胞基质,UBM的厚度为0.05-0.2mm,脱细胞基质为猪小肠粘膜下层、真皮、心包、羊膜、腹膜等。A biomaterial with improved bending properties, including decellularized bladder basement membrane UBM and acellular matrix, UBM is completely covered with acellular matrix, the thickness of UBM is 0.05-0.2mm, and the acellular matrix is porcine small intestinal submucosa, dermis, pericardium , amnion, peritoneum, etc.
生物材料的结构优选UBM为上下表层,以SIS为中间层,上下表层完全包覆中间层形成三明治结构。The structure of the biomaterial is preferably UBM as the upper and lower surface layers, SIS as the middle layer, and the upper and lower surface layers completely cover the middle layer to form a sandwich structure.
生物材料层间以真空层压的方式固定。The biomaterial layers are fixed by vacuum lamination.
真空层压的工艺参数为:真空压力为-50~-760mmHg,作用时间为0.5~72h。The process parameters of vacuum lamination are: the vacuum pressure is -50~-760mmHg, and the action time is 0.5~72h.
本发明的生物材料完全水化10min后的弯曲长度降低不超过50%。The bending length of the biological material of the present invention is not reduced by more than 50% after being fully hydrated for 10 minutes.
UBM由哺乳动物膀胱经机械方法除去浆膜、肌层、粘膜下层、粘膜肌层后脱细胞处理制得。UBM is made from the mammalian bladder by mechanical means to remove the serosa, muscular layer, submucosa, and muscularis mucosa after decellularization.
SIS由哺乳动物小肠经机械方法除去粘膜、浆膜层和肌层后脱细胞处理制得。SIS is produced by decellularization of the mammalian small intestine after mechanical removal of the mucosa, serosa and muscularis.
生物材料还可以添加药物,药物借助介质分布于生物材料层间或表面或层间和表面。Drugs can also be added to the biological material, and the drug is distributed between the layers or the surface of the biological material or between the layers and the surface by means of a medium.
实施例1Example 1
按照以下配比选择原材料,制备生物材料:Select raw materials according to the following proportions to prepare biological materials:
对照品:8层SISControl substance: 8-layer SIS
样品A:6层SIS+上下表层UBM,UBM表层厚度为0.05mmSample A: 6 layers of SIS + upper and lower surface layers of UBM, the thickness of the UBM surface layer is 0.05mm
样品B:6层SIS+上下表层UBM,UBM表层厚度为0.1mmSample B: 6 layers of SIS + upper and lower surface layers of UBM, the thickness of the UBM surface layer is 0.1mm
样品C:6层SIS+上下表层UBM,UBM表层厚度为0.2mmSample C: 6 layers of SIS + upper and lower surface layers of UBM, the thickness of the UBM surface layer is 0.2mm
采用真空层压工艺制为待测试样品。The samples to be tested were made by vacuum lamination process.
厚度测试:使用螺旋厚度仪对制成的对照品和样品进行检测,每批次样品随机检测5个点,结果为平均值。各组材料整体厚度无明显差异,结果如表1所示。Thickness test: Use a spiral thickness meter to test the prepared reference substance and samples, and randomly test 5 points for each batch of samples, and the results are the average value. There was no significant difference in the overall thickness of the materials in each group, and the results are shown in Table 1.
克重:使用分析天平对制成的对照品和样品进行单位面积重量测试。各组材料单位面积克重无明显差异,结果如表1所示。Gram weight: Use an analytical balance to test the weight per unit area of the prepared reference substance and samples. There was no significant difference in the weight per unit area of materials in each group, and the results are shown in Table 1.
表1测试样品的厚度和单位面积克重结果Table 1 The thickness of the test sample and the results of the grammage per unit area
弯曲长度测试方法:参考GB/T 18318.1-2009纺织品弯曲性能的测定第1部分:斜面法。取宽度为1cm,长度为20cm的材料,使用截面法测定未水化材料的弯曲长度和抗弯强度。将材料完全浸没于室温生理盐水中,浸泡时间为2min、10min,取出后同样的方法再次测定弯曲长度和抗弯刚度,每个样品重复5次取均值。测试结果如表2。弯曲长度定义为一端握持,另一端悬空的矩形试样在自重作用下弯曲至特定角度时的长度;抗弯刚度定义为单位宽度材料的微小弯矩变化与其相应曲率变化之比。Bending length test method: refer to GB/T 18318.1-2009 Determination of the Bending Properties of Textiles Part 1: Inclined Plane Method. Take a material with a width of 1 cm and a length of 20 cm, and use the section method to measure the bending length and flexural strength of the unhydrated material. The material was completely submerged in normal saline at room temperature for 2 minutes and 10 minutes. After taking it out, the bending length and bending stiffness were measured again in the same way, and each sample was repeated 5 times to obtain the average value. The test results are shown in Table 2. Bending length is defined as the length of a rectangular specimen held at one end and suspended at the other end when it is bent to a specific angle under its own weight; flexural stiffness is defined as the ratio of the small bending moment change per unit width of the material to its corresponding curvature change.
表2弯曲长度、抗弯刚度的测试结果Table 2 The test results of bending length and bending stiffness
从表2的弯曲长度和抗弯刚度结果可知,样品A、B、C水化后弯曲长度降低不超过水化前的50%,也就是说,采用本发明的表层为UBM,UBM完全包覆SIS的结构,且UBM的厚度在0.05-0.2mm范围内,使整体的生物材料在水化10min后弯曲长度降低仍不超过水化前的50%,并且在生物材料整体厚度不变的情况下,UBM的厚度越厚,弯曲长度、抗弯刚度水化后降低更少,操作性能更好。From the results of bending length and bending stiffness in Table 2, it can be seen that the bending length of samples A, B, and C after hydration decreases by no more than 50% of that before hydration, that is to say, the surface layer of the present invention is UBM, and the UBM is completely covered The structure of the SIS, and the thickness of the UBM is in the range of 0.05-0.2mm, so that the bending length of the overall biological material is reduced by 50% after hydration for 10 minutes, and the overall thickness of the biological material remains unchanged. , the thicker the thickness of UBM, the lower the bending length and bending stiffness after hydration, and the better the operability.
临床研究方案摘要:评价生物补片用于治疗腹壁疝的有效性和安全性的随机、单盲、平行对照、多中心临床试验,受试者开放术式150例,其中试验组75例、对照组75例。试验器械为样品A(试验组),对照器械为对照品(猪小肠粘膜下层产品),主要观察指标为术后6个月复发率,次要安全性评价指标为术后发热、手术区域血肿/浆液肿、切口感染评估、疼痛评分、腹股沟区域异物感、过敏反应。Summary of clinical research protocol: a randomized, single-blind, parallel-controlled, multi-center clinical trial evaluating the effectiveness and safety of biological mesh in the treatment of abdominal wall hernia, with 150 subjects undergoing open surgery, including 75 cases in the test group and control group Group of 75 cases. The test device is sample A (test group), the control device is the reference product (porcine small intestinal submucosa product), the main observation index is the recurrence rate at 6 months after operation, and the secondary safety evaluation indexes are postoperative fever, hematoma/ Serous swelling, wound infection assessment, pain score, foreign body sensation in groin area, anaphylaxis.
研究结果:Research result:
术后6个月复发率6-month recurrence rate
试验组:无。Test group: none.
对照组:2例复发。Control group: 2 cases of recurrence.
术后18个月复发率18-month postoperative recurrence rate
试验组:无。Test group: none.
对照组:4例复发。Control group: 4 cases of recurrence.
其他指标:Other indicators:
试验组补片易操作性优于对照组补片,反映在试验组的补片固定时间短于对照组,由此带来手术操作时间显著短于对照组。The ease of operation of the patch in the test group was better than that in the control group, reflecting that the fixation time of the patch in the test group was shorter than that in the control group, which resulted in significantly shorter operation time than the control group.
表3补片操作时间Table 3 patch operation time
从上述的临床试验结果可知,本发明的生物材料整体具有良好的操作手感,能够在水化后保持材料的硬挺度,贴合度好,利于手术缝合操作,缩短补片固定时间。From the above clinical test results, it can be seen that the biological material of the present invention has a good operating feel as a whole, can maintain the stiffness of the material after hydration, has a good fit, facilitates surgical suturing operations, and shortens the fixation time of the patch.
上面对本发明的实施方式作了详细说明,但是本发明并不限于上述实施方式。即使对本发明做出各种变化,倘若这些变化属于本发明权利要求及其等同技术的范围之内,则仍落入在本发明的保护范围之中。The embodiments of the present invention have been described above in detail, but the present invention is not limited to the above embodiments. Even if various changes are made to the present invention, if these changes fall within the scope of the claims of the present invention and equivalent technologies, they still fall within the protection scope of the present invention.
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111160236.8A CN113908343B (en) | 2021-09-30 | 2021-09-30 | Biomaterial with improved bending performance |
US17/518,124 US20220054707A1 (en) | 2016-04-25 | 2021-11-03 | Biological material with composite extracellular matrix components |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111160236.8A CN113908343B (en) | 2021-09-30 | 2021-09-30 | Biomaterial with improved bending performance |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113908343A CN113908343A (en) | 2022-01-11 |
CN113908343B true CN113908343B (en) | 2023-01-20 |
Family
ID=79237445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111160236.8A Active CN113908343B (en) | 2016-04-25 | 2021-09-30 | Biomaterial with improved bending performance |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113908343B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106039404A (en) * | 2015-04-08 | 2016-10-26 | 上海宏创医疗科技有限公司 | Preparation method for extracellular matrix (ECM) composite biological patch |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101366979B (en) * | 2008-09-03 | 2012-08-29 | 陕西瑞盛生物科技有限公司 | Tissue patch and preparation method thereof |
WO2010099463A2 (en) * | 2009-02-27 | 2010-09-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Joint bioscaffolds |
CN105664257B (en) * | 2016-03-01 | 2019-02-19 | 上海卓阮医疗科技有限公司 | A composite soft tissue repair material with stable repair area |
US20220054707A1 (en) * | 2016-04-25 | 2022-02-24 | Shanghai Zhuoruan Medical Technologies Co., Ltd | Biological material with composite extracellular matrix components |
CN105920669B (en) * | 2016-04-25 | 2019-03-29 | 上海卓阮医疗科技有限公司 | A kind of compound cells epimatrix ingredients Biogenic material |
CN107335097B (en) * | 2017-06-16 | 2020-09-15 | 卓阮医疗科技(苏州)有限公司 | A composite soft tissue repair material with improved operating feel |
CN107213516A (en) * | 2017-06-16 | 2017-09-29 | 卓阮医疗科技(苏州)有限公司 | A kind of thin layer composite tissue renovation material of stable mechanical property and preparation method thereof |
CN107320786B (en) * | 2017-06-16 | 2020-06-23 | 卓阮医疗科技(苏州)有限公司 | Slow-release anti-infection composite soft tissue repair material and preparation method thereof |
-
2021
- 2021-09-30 CN CN202111160236.8A patent/CN113908343B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106039404A (en) * | 2015-04-08 | 2016-10-26 | 上海宏创医疗科技有限公司 | Preparation method for extracellular matrix (ECM) composite biological patch |
Non-Patent Citations (1)
Title |
---|
"PDO-SIS补片的生物力学性能及其对大鼠腹壁缺损的修复作用";谢亚运等;《解放军医学杂志》;20170501;第42卷;第366-371页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113908343A (en) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107007886B (en) | A kind of biological tissue's host material, preparation method and its usage | |
WO2017148255A1 (en) | Composite soft tissue repairing material for stabilizing repair region | |
AU2007231131B2 (en) | Improvements relating to decellularisation of tissue matrices for bladder implantation | |
WO1998022157A1 (en) | Collagen material and process for producing the same | |
JP2003509129A (en) | Resorbable implant material | |
WO2024178882A1 (en) | Method for preparing dry amniotic membrane and use thereof | |
CN101595211A (en) | Skin substitute and its preparation method and use | |
EP3572103A1 (en) | Biological tissue matrix material, preparation method therefor and use thereof in otological repair material | |
CN108883209A (en) | Fetus supporting tissue product and application method | |
Lai et al. | Development of a cellulose-based prosthetic mesh for pelvic organ prolapse treatment: In vivo long-term evaluation in an ewe vagina model | |
CN113908343B (en) | Biomaterial with improved bending performance | |
US10583219B1 (en) | Multilayer bioabsorbable construct and methods of use | |
JP5886048B2 (en) | Minimal tissue adherent implantable material | |
Meyer et al. | A new biocompatible material (Lyoplant®) for the therapy of congenital abdominal wall defects: first experimental results in rats | |
Ai et al. | Experimental study of a new original mesh developed for pelvic floor reconstructive surgery | |
CN119113221A (en) | A transparent decellularized biomaterial and its preparation method and application | |
CN116271243A (en) | Acellular matrix composite rotator cuff patch | |
CN204219093U (en) | A kind of degradable spherical faux bladder | |
CN110433340B (en) | Acellular matrix urethral suspension repair material and preparation method and application thereof | |
RU2328232C1 (en) | Method of women's tension enuresis treatment | |
Liu et al. | A bionic 3D-printed hydrogel microneedle of composite mesh for abdominal wall defect repair | |
CN104188734A (en) | Degradable spherical artificial bladder | |
US20240189484A1 (en) | Composite decellularized matrix membrane and use thereof | |
CN112755249B (en) | Mechanical property enhanced acellular spinal cord biomaterial stent and preparation method and application thereof | |
CN118161672A (en) | Anti-deformation acellular matrix composite membrane and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A biomaterial with improved bending performance Granted publication date: 20230120 Pledgee: Shanghai Bank Co.,Ltd. Suzhou Branch Pledgor: ZHUORUAN MEDICAL TECHNOLOGY (SUZHOU) Co.,Ltd. Registration number: Y2025980003070 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |